Pathophysiological targets in OA therapy  by Pelletier, Jean-Pierre
Osteoarthritis and Cartilage (1999) 7, 353–354
? 1999 OsteoArthritis Research Society International 1063–4584/99/030353+02 $12.00/0
Article No. joca.1998.0196, available online at http://www.idealibrary.com onPathophysiological targets in OA therapy
BY JEAN-PIERRE PELLETIER
Osteoarthritis Research Unit, Centre de recherche, Centre Hospitalier de l’Universite´ de
Montre´al—Campus Notre-Dame, Montre´al, Que´bec, CanadaMMPs
iNOS
IL-1b
COX-2
Pathological changes in osteoarthritis
• Increased production of
prostaglandins, nitric
oxide, cytokines and
other inflammatory
mediators
• Osteophyte formation
• Cartilage erosion
• Swelling
• Pain
FIG. 1.OVER the last decade, there have been several
interesting advances in the treatment of osteo-
arthritis (OA). A clearer understanding of the
pathophysiology of OA (Fig. 1) has facilitated the
development of new approaches for treatments
aimed at specifically and e#ectively retarding the
progression of this disease.
Recently, the drugs used to treat OA have been
classified as being either symptomatic or structure
(disease) modifying. A better understanding of the
mechanisms of joint damage and repair has led to
the development of a new class of molecules that
inhibits one or several OA catabolic processes,
while some of the drugs now used are being evalu-
ated for their potential to alter the degenerative
process.
The following contains a review of data on new
molecules currently under evaluation, with an353emphasis on recent developments concerning a
new class of agents and their potential therapeutic
use in human OA. Following this is a description
of the newly envisaged approach to deliver the
biological agents that have demonstrated
beneficial therapeutic properties.
To date, no drug having disease modifying
activity is available to treat OA. Studies have
revealed strong evidence that nitric oxide (NO)
produced via the elevation of inducible NO syn-
thase (iNOS) is injurious to OA joint tissues [1, 2],
and that selective inhibition of this enzyme
would provide a novel therapeutic approach to
treatment. In experimental models of inflammatory
arthritis and OA, treatment with compounds that
inhibit iNOS activity either nonselectively or
selectively has been shown to reduce the severity
of pathological lesions.
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matrix of cartilage in OA has been well docu-
mented, and metalloproteases (MMP) are believed
to play a major role in this disease. Inhibition of
the synthesis/activity of these enzymes as a treat-
ment for OA has been the focus of intensive
research [3]. Although there are natural biological
inhibitors of MMP (e.g. tissue inhibiting metallo-
protease; TIMP), their therapeutic use has been
very limited due mainly to obstacles in the admin-
istration of proteins, and similar limitations exist
for synthetic peptides. To date, the most promising
agents are chemical molecules that can block the
activity of MMP. Another attractive option to
decreasing MMP levels is to interfere with the
transcription factors of their promoter sequences.
At present, factors under study act in a rather
nonspecific manner.
A number of biological agents have also
demonstrated potentially beneficial therapeutic
properties both in-vitro and in some in-vivo models
of arthritis including OA. These include proinflam-
matory cytokine inhibitors, cytokine soluble
receptors and antiinflammatory cytokines. A
major stumbling block in the use of biological
molecules is the method used to deliver the agent
and its applicability to the clinical scenario.
Degradation of the protein after oral admin-
istration poses a problem, and if injected system-
atically, the large amount required and the need
for frequent injections are often deterrents. This
last route of administration can induce adverse
e#ects including an immunological reaction with
the appearance of a neutralizing antibody. The
necessity of maintaining a sustained level of the
agents over time is the major concern with this
type of therapy.
In the last few years, much attention has been
focused on the use of gene transfer techniques as a
method of delivery. Many techniques have been
developed using various genes, and a great deal of
work is currently devoted to these techniques to
facilitate the transfer of genes into joint cells and
tissues, both in vitro and in vivo. The advantages ofthis approach in the treatment of OA are multiple,
and include the identification of a very specific
target, a consistently high local concentration in
the joint of the therapeutic protein, and the main-
tenance of a sustained delivery over time. More-
over, there is hope that this type of therapy will
reduce the incidence of side e#ects.
Two main systems, viral and non-viral, are cur-
rently used for gene transfer to cells. At this time,
the viral system is favored for some proteins
because it generally allows for a very e#ective
transfer to a large percentage of cells while main-
taining a sustained high level of protein expres-
sion that can be extended over significant periods
of time.
Although the treatment of OA using gene
therapy is very promising, this technique is still in
the very early stage of development, and much
work remains to be done, particularly on the
in-vivo development of this technology for
humans. Moreover, the selection of the gene(s)
that would o#er the best protection against OA
remains
to be determined. Some proteins such as the
interleukin-1 receptor antagonist (IL-1Ra) have
elicited much attention in OA therapy, and results
of these studies are now emerging.References
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